[go: up one dir, main page]

WO2002043753A8 - Remedies for chronic hepatitis b - Google Patents

Remedies for chronic hepatitis b

Info

Publication number
WO2002043753A8
WO2002043753A8 PCT/JP2001/010490 JP0110490W WO0243753A8 WO 2002043753 A8 WO2002043753 A8 WO 2002043753A8 JP 0110490 W JP0110490 W JP 0110490W WO 0243753 A8 WO0243753 A8 WO 0243753A8
Authority
WO
WIPO (PCT)
Prior art keywords
chronic hepatitis
remedies
lactoferrin
prebiotics
probiotics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2001/010490
Other languages
English (en)
French (fr)
Other versions
WO2002043753A1 (en
Inventor
Akiharu Watanabe
Kiyohiro Higuchi
Hirotoshi Hayasawa
Susumu Teraguchi
Koji Yamauchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morinaga Milk Industry Co Ltd
Original Assignee
Morinaga Milk Industry Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morinaga Milk Industry Co Ltd filed Critical Morinaga Milk Industry Co Ltd
Priority to JP2002545723A priority Critical patent/JP4087249B2/ja
Priority to KR10-2003-7001705A priority patent/KR20030045025A/ko
Priority to HK04100492.9A priority patent/HK1057489B/xx
Publication of WO2002043753A1 publication Critical patent/WO2002043753A1/ja
Publication of WO2002043753A8 publication Critical patent/WO2002043753A8/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PCT/JP2001/010490 2000-11-30 2001-11-30 Remedies for chronic hepatitis b Ceased WO2002043753A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2002545723A JP4087249B2 (ja) 2000-11-30 2001-11-30 Ｂ型慢性肝炎治療剤
KR10-2003-7001705A KR20030045025A (ko) 2000-11-30 2001-11-30 Ｂ형 만성 간염 치료제
HK04100492.9A HK1057489B (en) 2000-11-30 2001-11-30 Medicament for treating chronic hepatitis b

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000365299 2000-11-30
JP2000-365299 2000-11-30

Publications (2)

Publication Number Publication Date
WO2002043753A1 WO2002043753A1 (en) 2002-06-06
WO2002043753A8 true WO2002043753A8 (en) 2003-03-06

Family

ID=18836097

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/010490 Ceased WO2002043753A1 (en) 2000-11-30 2001-11-30 Remedies for chronic hepatitis b

Country Status (4)

Country Link
JP (1) JP4087249B2 (ja)
KR (1) KR20030045025A (ja)
CN (1) CN1287855C (ja)
WO (1) WO2002043753A1 (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100421656C (zh) * 2002-11-07 2008-10-01 明尼苏达大学评议会 乌索脱氧胆酸在制备治疗与出血相关的神经系统损伤的药物中的用途
JP2005247780A (ja) * 2004-03-05 2005-09-15 Masakazu Maruyama ウイルス性肝炎治療剤
US20070224285A1 (en) 2004-03-31 2007-09-27 Calpis Co., Ltd Agent for Preventing or Suppressing Hepatopathy and Functional Food for Preventing or Suppressing Hepatopathy
US20090082269A1 (en) 2005-06-29 2009-03-26 Nrl Pharma, Inc. Agent for ameliorating heavy metal-induced disorders, and medicinal composition, food and cosmetic containing the same
WO2008047391A1 (en) * 2006-10-17 2008-04-24 S.I.F.Fr.A. Farmaceutici Srl Nutriceutic composition comprising lactoferrin and proteasic probiotics
BRPI0917172A2 (pt) * 2008-08-28 2015-08-04 Chr Hansen As Composição bacteriana
CN107184613A (zh) * 2017-05-23 2017-09-22 山东大学 一种促进乙型肝炎病毒清除的益生菌组合物及其应用
CN119040216B (zh) * 2024-10-25 2025-02-11 广东省科学院微生物研究所(广东省微生物分析检测中心) 一株具有抗乙型肝炎病毒功能的长双歧杆菌gy2及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2532911B2 (ja) * 1988-03-01 1996-09-11 森永乳業株式会社 有用細菌の腸内定着を促進する組成物
CA2338884A1 (en) * 1998-07-30 2000-02-10 Morinaga Milk Industry Co., Ltd. Liver function ameliorating agents
JP2000325046A (ja) * 1999-05-19 2000-11-28 Meiji Milk Prod Co Ltd 肝炎を予防および治療する食品もしくは医薬品

Also Published As

Publication number Publication date
JP4087249B2 (ja) 2008-05-21
HK1057489A1 (en) 2004-04-08
CN1287855C (zh) 2006-12-06
WO2002043753A1 (en) 2002-06-06
KR20030045025A (ko) 2003-06-09
CN1446099A (zh) 2003-10-01
JPWO2002043753A1 (ja) 2004-04-02

Similar Documents

Publication Publication Date Title
CA2404387A1 (en) Theanine compositions for promoting sleep
WO2001027109A3 (de) Tert.-butyl-(7-methyl-imidazo[1,2-a]pyridin-3-yl)-amin-derivate
AU2002346296A1 (en) Block copolymer reduced in impurity content, polymeric carrier, pharmaceutical preparations in polymeric form and process for the preparation of the same
EP0966969A4 (en) ANTI-STRESS ACTIVE AND FUNCTIONAL NUTRIENTS WITH ANTI-STRESS EFFECTS
WO2003094836A3 (en) Methods and products for enhancing immune responses using imidazoquinoline compounds
WO2002070438A3 (en) Compositions for delivering bisphosphonates
WO1999039694A3 (en) Compositions containing organic compounds
EP1283054A4 (en) MEDICAMENTS FOR TREATING THE COMPLICATIONS OF DIABETES AND NEUROPATHIES AND USE THEREOF
WO2006125819A3 (fr) Forme medicamenteuse orale, microparticulaire, anti-mesusage
HUP0303278A3 (en) Freeze-dried pantoprazole preparation, process for its preparation and pantoprazole injection
WO2000053149A3 (en) Method and composition for administering a cyclooxygenase-2 inhibitor
WO2007144169A3 (en) Entacapone-derivatives
EP1228708A3 (en) Milk derived basic protein fraction as agents for improving lipid metabolism and reducing high blood pressure
WO2002043753A8 (en) Remedies for chronic hepatitis b
AU2003246567A1 (en) Administration form for the oral administration of active substances, vitamins, and/or nutrients
WO2002015959A3 (en) Compounds and compositions for delivering active agents
WO2006012213A3 (en) Composition and method for delivery of phytochemicals
WO2001030383A3 (de) Arzneimittel für die toleranzinduktion
AU2003246566A1 (en) Administration form for the oral administration of active substances, vitamins, and/or nutrients
WO2002000208A3 (de) Kombinationspräparate von 3-n-formylhydroxylaminopropylphosphonsäurederivaten oder 3-n-acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen
EP1550443A4 (en) COMPOSITION AGAINST STRESS-BASED DISEASES
AU2001289762A1 (en) Pharmaceutical extemporary compositions
WO2001030372A3 (de) Zubereitungen pharmazeutischer wirkstoffe
WO2001074340A3 (en) Drug combination for the treatment of headache comprising mirtazapine and paracetamol or a non-steroidal anti-inflammatory drug
EP1219297A4 (en) ACTIVE AGENTS AGAINST FATTY ADDICTION

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CN ID JP KR

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1020037001705

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 018139817

Country of ref document: CN

CFP Corrected version of a pamphlet front page

Free format text: UNDER (72) REPLACE "ETRAGUCHI" BY "TERAGUCHI"

WWE Wipo information: entry into national phase

Ref document number: 2002545723

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 1020037001705

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: 1020037001705

Country of ref document: KR

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)